---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027274"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2026-06-04T20:15:33+00:00"
generated_at: "2026-06-04T20:50:50.578900+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech terminates Catalyst advisory agreement; shifts to soft tissue/bone fusion strategy

## Summary
- On June 2, 2026, Sanara MedTech and The Catalyst Group mutually terminated their March 2023 advisory agreement.
- Termination due to shift in strategy to focus on soft tissue repair and bone fusion surgical products.
- No fee or penalty paid in connection with termination; certain covenants (indemnification, confidentiality) remain in effect.
- Chairman Ronald T. Nixon is founder/managing partner of Catalyst and holds >5% beneficial ownership of Sanara MedTech.

## SEC filing metadata
- accession: 0001493152-26-027274
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2026-06-04T20:15:33+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315226027274/0001493152-26-027274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315226027274/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027274
- JSON: https://secwatch.observer/filing/0001493152-26-027274.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027274.txt

## Key facts
- Material Agreements
  Sanara MedTech Inc. terminated Services Agreement with The Catalyst Group, Inc. (effective 2026-06-02).
  - Action: termination
  - Counterparty: The Catalyst Group, Inc.
  - Effective: 2026-06-02
  source text: On June 2, 2026, in connection with the Company’s shift in strategy to focus on soft tissue repair and bone fusion products for the surgical market, the Company entered into a Mutual Termination Agreement (the “Mutual Termination Agreement”) with Catalyst, pursuant to which the parties agreed to terminate the Services Agreement, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315226027274/0001493152-26-027274-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.